Cases & Deals

Perlan establishes global patent portfolio for ICAM1 antibodies

Clients Perlan Therapeutics, Inc.

Jones Day represents Perlan Therapeutics, Inc. in connection with the global patent portfolio for ICAM1 antibodies for the treatment of rhinovirus and other respiratory infections.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.